Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development

International Journal of Cancer

Volumn 106, Issue 4, 2003, Pages 472-479

  Van der Velden, Pieter A ^a   Zuidervaart, Wieke ^a   Hurks, Monique H M H ^a   Pavey, Sandra ^c   Ksander, Bruce R ^b   Krijgsman, Elise ^a   Frants, Rune R ^a   Tensen, Cornelis P ^a   Willemze, Rein ^a   Jager, Martine J ^a   Gruis, Nelleke A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Microarray; TIMP3; Uveal melanoma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER MORTALITY; CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; DNA MICROARRAY; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METASTASIS; MACROPHAGE ACTIVATION; METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TUMOR GROWTH; UNINDEXED SEQUENCE; UVEA MELANOMA;

AZACITIDINE; DISEASE PROGRESSION; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA PROBES; DOWN-REGULATION; ENZYME INHIBITORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; MELANOMA; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; UVEAL NEOPLASMS;

EID: 0043095382     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11262     Document Type: Article

References (29)

1. Diener-West M, Hawkins BS, Markowitz JA, Schachat AP. A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol 1992;110:245-50.
2. Gamel JW, McLean IW, McCurdy JB. Biologic distinctions between cure and time to death in 2892 patients with intraocular melanoma. Cancer 1993;71:2299-305.
3. McLean IW. The biology of haematogenous metastasis in human uveal malignant melanoma. Virchows Arch A Pathol Anat Histopathol 1993;422:433-7.
4. Mooy CM, De Jong PT. Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol 1996;41:215-28.
5. Foss AJ, Alexander RA, Jefferies LW, Hungerford JL, Harris AL, Lightman S. Microvessel count predicts survival in uveal melanoma. Cancer Res 1996;56:2900-3.
6. Makitie T, Summanen P, Tarkkanen A, Kivela T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci 2001;42:1414-21.
7. Ma D, Luyten GP, Luider TM, Niederkorn JY. Relationship between natural killer cell susceptibility and metastasis of human uveal melanoma cells in a murine model. Invest Ophthalmol Vis Sci 1995;36:435-41.
8. Hurks HM, Metzelaar-Blok JA, Barthen ER, Zwinderman AH, De Wolff-Rouendaal D, Keunen JE, Jager MJ. Expression of epidermal growth factor receptor: risk factor in uveal melanoma. Invest Ophthalmol Vis Sci 2000;41:2023-7.
9. DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, Chen Y, Su Ya, Trent JM. Use of a cDNA microarray to analyze gene expression patterns in human cancer. Nat Genet 1996;14:457-60.
10. van der Velden PA, Metzelaar-Blok JA, Bergman W, Monique H, Hurks H, Frants RR, Gruis NA, Jager MJ. Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma. Cancer Res 2001;61:5303-6.
11. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, Trent JM, Meltzer PS, Hendrix MJ. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999;155:739-52.
12. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996;6:986-94.
13. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, Baylin SB, Graff JR. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 1999;59:798-802.
14. Kerstens HM, Poddighe PJ, Hanselaar AG. A novel in situ hybridization signal amplification method based on the deposition of biotinylated tyramine. J Histochem Cytochem 1995;43:347-52.
15. Fariss RN, Apte SS, Olsen BR, Iwata K, Milam AH. Tissue inhibitor of metalloproteinases-3 is a component of Bruch's membrane of the eye. Am J Pathol 1997;150:323-8.
16. Weber BH, Vogt G, Pruett RC, Stohr H, Felbor U. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy. Nat Genet 1994;8:352-6.
17. McElligott AM, Baker AH, McGlynn H. Matrix metalloproteinase and tissue inhibitor of metalloproteinase regulation of the invasive potential of a metastatic renal cell line. Biochem Soc Trans 1997;25:147S.
18. Michael M, Babic B, Khokha R, Tsao M, Ho J, Pintilie M, Leco K, Chamberlain D, Shepherd FA. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol. 1999;17:1802-8.
19. Spurbeck WW, Ng CY, Strom TS, Vanin EF, Davidoff AM. Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model. Blood 2002;100:3361-8.
20. Hofmann UB, Westphal JR, van Muijen GN, Ruiter DJ. Matrix metalloproteinases in human melanoma. J Invest Dermatol 2000;115:337-44.
21. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000;1477:267-83.
22. Ahonen M, Baker AH, Kahari VM. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res 1998;58:2310-15.
23. Kwon BS, Halaban R, Chintamaneni C. Molecular basis of mouse Himalayan mutation. Biochem Biophys Res Commun 1989;161:252-60.
24. Liu YW, Chang KJ, Liu YC. DNA methylation is not involved in growth regulation of gene expression of proliferating cell nuclear antigen. Exp Cell Res 1993;208:479-84.
25. De Cabo SF, Hazen MJ, Molero ML, Fernandez-Piqueras J. s-adenosyl-L-homocysteine: a non-cytotoxic hypomethylating agent. Experientia 1994;50:658-9.
26. Kauwell GP, Lippert BL, Wilsky CE, Herrlinger-Garcia K, Hutson AD, Theriaque DW, Rampersaud GC, Cerda JJ, Bailey LB. Folate status of elderly women following moderate folate depletion responds only to a higher folate intake. J Nutr 2000;130:1584-90.
27. Repp AC, Mayhew ES, Apte S, Niederkorn JY. Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J Immunol 2000;165:710-5.
28. Apte RS, Sinha D, Mayhew E, Wistow GJ, Niederkorn JY. Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol 1998;160:5693-6.
29. Folberg R, Pe'er J, Gruman LM, Woolson RF, Jeng G, Montague PR, Moninger TO, Yi H, Moore KC. The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case-control study. Hum Pathol 1992;23:1298-305.